167 related articles for article (PubMed ID: 36228178)
1. Enhancing Administrative Claims Data: Feasibility, Validation and Application of Linking Medicare Claims Data and National Marrow Donor Program Search Data.
Preussler JM; Meyer CL; Sees Coles JA; Yoo D; Mau LW; Garrett ND; Auletta JJ
JCO Clin Cancer Inform; 2022 Oct; 6():e2200069. PubMed ID: 36228178
[TBL] [Abstract][Full Text] [Related]
2. Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myelogenous Leukemia.
Mau LW; Preussler JM; Meyer CL; Senneka MK; Wallerstedt S; Steinert P; Khera N; Saber W
Transplant Cell Ther; 2022 Dec; 28(12):852-858. PubMed ID: 36170959
[TBL] [Abstract][Full Text] [Related]
3. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.
Auletta JJ; Kou J; Chen M; Bolon YT; Broglie L; Bupp C; Christianson D; Cusatis RN; Devine SM; Eapen M; Hamadani M; Hengen M; Lee SJ; Moskop A; Page KM; Pasquini MC; Perez WS; Phelan R; Riches ML; Rizzo JD; Saber W; Spellman SR; Stefanski HE; Steinert P; Tuschl E; Yusuf R; Zhang MJ; Shaw BE
Transplant Cell Ther; 2023 Jun; 29(6):346.e1-346.e10. PubMed ID: 36924931
[TBL] [Abstract][Full Text] [Related]
4. Barriers to Access to Hematopoietic Cell Transplantation among Patients with Acute Myeloid Leukemia in Virginia.
Mock J; Meyer C; Mau LW; Nguyen C; Arora P; Heron C; Balkrishnan R; Burns L; Devine S; Ballen K
Transplant Cell Ther; 2021 Oct; 27(10):869.e1-869.e9. PubMed ID: 34224915
[TBL] [Abstract][Full Text] [Related]
5. Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products.
Auletta JJ; Novakovich JL; Stritesky GL; Newman J; Fridy-Chesser ST; Hailperin K; Devine SM
Transplant Cell Ther; 2021 Feb; 27(2):133-141. PubMed ID: 33830022
[TBL] [Abstract][Full Text] [Related]
6. Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program.
Pidala J; Mupfudze TG; Payton T; Barker J; Perales MA; Shaw BE; Fernández-Viña M; Burns LJ; Dehn J
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2501-2506. PubMed ID: 31419569
[TBL] [Abstract][Full Text] [Related]
7. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
[TBL] [Abstract][Full Text] [Related]
8. Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients.
Jabo B; Morgan JW; Martinez ME; Ghamsary M; Wieduwilt MJ
PLoS One; 2017; 12(4):e0174760. PubMed ID: 28384176
[TBL] [Abstract][Full Text] [Related]
9. Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities.
Preussler JM; Mau LW; Majhail NS; Meyer CL; Denzen EM; Edsall KC; Farnia SH; Silver A; Saber W; Burns LJ; Vanness DJ
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1738-1746. PubMed ID: 27184624
[TBL] [Abstract][Full Text] [Related]
10. Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings.
Dunavin N; Mau LW; Meyer CL; Divine C; Abdallah AO; Leppke S; D'Souza A; Denzen E; Saber W; Burns LJ; Ganguly S
Biol Blood Marrow Transplant; 2020 Apr; 26(4):805-813. PubMed ID: 31917269
[TBL] [Abstract][Full Text] [Related]
11. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Passweg JR; Labopin M; Christopeit M; Cornelissen J; Pabst T; Socié G; Russel N; Yakoub-Agha I; Blaise D; Gedde-Dahl T; Labussière-Wallet H; Malladi R; Forcade E; Maury S; Polge E; Lanza F; Gorin NC; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2020 Apr; 26(4):659-664. PubMed ID: 31759159
[TBL] [Abstract][Full Text] [Related]
12. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
[TBL] [Abstract][Full Text] [Related]
13. T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia.
How J; Slade M; Vu K; DiPersio JF; Westervelt P; Uy GL; Abboud CN; Vij R; Schroeder MA; Fehniger TA; Romee R
Biol Blood Marrow Transplant; 2017 Apr; 23(4):648-653. PubMed ID: 28087457
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia.
Menon NN; Jenkins LM; Cui H; Jenkins C; Anwer F; Yeager AM; Katsanis E
Ann Hematol; 2016 Mar; 95(4):637-44. PubMed ID: 26787415
[TBL] [Abstract][Full Text] [Related]
16. Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia.
Bhatt VR; Chen B; Gyawali B; Lee SJ
Bone Marrow Transplant; 2018 Oct; 53(10):1288-1294. PubMed ID: 29588500
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century.
Yanada M; Takami A; Yamasaki S; Arai Y; Konuma T; Uchida N; Najima Y; Fukuda T; Tanaka M; Ozawa Y; Ikegame K; Takanashi M; Ichinohe T; Okamoto S; Atsuta Y; Yano S
Ann Hematol; 2020 Jun; 99(6):1351-1360. PubMed ID: 32363416
[TBL] [Abstract][Full Text] [Related]
18. Likelihood of Proceeding to Allogeneic Hematopoietic Cell Transplantation in the United States after Search Activation in the National Registry: Impact of Patient Age, Disease, and Search Prognosis.
Dehn J; Chitphakdithai P; Shaw BE; McDonald AA; Devine SM; Burns LJ; Spellman S
Transplant Cell Ther; 2021 Feb; 27(2):184.e1-184.e13. PubMed ID: 33045385
[TBL] [Abstract][Full Text] [Related]
19. Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources.
Ballen KK; Joffe S; Brazauskas R; Wang Z; Aljurf MD; Akpek G; Dandoy C; Frangoul HA; Freytes CO; Khera N; Lazarus HM; LeMaistre CF; Mehta P; Parsons SK; Szwajcer D; Ustun C; Wood WA; Majhail NS
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1819-27. PubMed ID: 25064747
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
Rashidi A; Hamadani M; Zhang MJ; Wang HL; Abdel-Azim H; Aljurf M; Assal A; Bajel A; Bashey A; Battiwalla M; Beitinjaneh AM; Bejanyan N; Bhatt VR; Bolaños-Meade J; Byrne M; Cahn JY; Cairo M; Ciurea S; Copelan E; Cutler C; Daly A; Diaz MA; Farhadfar N; Gale RP; Ganguly S; Grunwald MR; Hahn T; Hashmi S; Hildebrandt GC; Holland HK; Hossain N; Kanakry CG; Kharfan-Dabaja MA; Khera N; Koc Y; Lazarus HM; Lee JW; Maertens J; Martino R; McGuirk J; Munker R; Murthy HS; Nakamura R; Nathan S; Nishihori T; Palmisiano N; Patel S; Pidala J; Olin R; Olsson RF; Oran B; Ringden O; Rizzieri D; Rowe J; Savoie ML; Schultz KR; Seo S; Shaffer BC; Singh A; Solh M; Stockerl-Goldstein K; Verdonck LF; Wagner J; Waller EK; De Lima M; Sandmaier BM; Litzow M; Weisdorf D; Romee R; Saber W
Blood Adv; 2019 Jun; 3(12):1826-1836. PubMed ID: 31201170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
